iP-OSTEO – Induced pluripotent stem cell seeded active osteochondral nanofibrous scaffolds

The iP‑OSTEO project focuses on development of novel cell‑based scaffolds for bone and cartilage repair and will deliver an effective treatment method for patients with poor regenerative capacity. The involved institutions will also help in better integration of academic and industrial stakeholders across Europe as they strengthen the partnerships and promote knowledge transfer across national borders and across different sectors.

iP-Osteo.
iP-Osteo.

In February 2019, the MSCA‑RISE project iP‑Osteo commenced work with the participation of Fraunhofer IGB and will reach its goals by creating an international and interdisciplinary training program. Seven companies (SMEs) and seven academic institutions across the European Union will join their forces through dedicated secondments. The activities will involve networking, research, training, workshop and dissemination secondments. The project has in total 239 secondments involving exchange of early‑stage and experienced researchers. The consortium is bonded by Dr. Eva Filova, a young scientist with experience in bone and cartilage tissue engineering.

A total of 14 institutions from ten European countries are conducting research on this novel technology, which combines iPSCs with improved regeneration capacity and nanostructured scaffolds based on electrospun scaffolds as well as a drug delivery system stimulating cell regeneration based on electrosprayed and spray‑dried particles. The system will deliver a novel treatment method for older patients, for which the current cellular and cell‑free methods are ineffective.

The project has 169 ESR secondment months leading to training of new generation of scientists with international connection and knowledge of intrasectorial environment, who will help diseased people by providing novel therapeutic methods.

Project information

Project title

iP-OSTEO – Induced pluripotent stem cell seeded active osteochondral nanofibrous scaffolds

 

Project duration

February 2019 – January 2023

 

Project partners

  • Ústav experimentální medicíny AV ČR, v. v. i., Czechia (Coordination)
  • InoCure s.r.o., Czechia
  • Széchenyi István University, Hungary
  • OSPIN GmbH, Germany
  • Bioneer A/S, Denmark
  • OrthoSera GmbH, Austria
  • University College London, United Kingdom
  • Hochschule Rhein-Waal, Germany
  • LLS ROWIAK LaserLabSolutions GmbH, Germany
  • Corticalis AS, Norway
  • Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB, Germany
  • BIOFABICS LDA, Portugal
  • Scinus Cell Expansion B.V., Netherlands
  • Instytut Podstawowych Problemów Techniki Polskiej Akademii Nauk, Poland

Funding

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no 824007.